We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PerkinElmer Acquires Spectral Genomics
News

PerkinElmer Acquires Spectral Genomics

PerkinElmer Acquires Spectral Genomics
News

PerkinElmer Acquires Spectral Genomics

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "PerkinElmer Acquires Spectral Genomics"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PerkinElmer, Inc. has announced the acquisition of the assets of Spectral Genomics, Inc. Spectral Genomics' array products and analysis software help pharmaceutical, biotechnology, cytogenetic and clinical researchers identify chromosomal abnormalities related to the study of cancer and pre- and post-natal genetic disorders.

The company's proprietary Array CGH (Comparative Genome Hybridization) technology is designed to provide a high-resolution global view of the human genome, enabling researchers to identify the exact location of any chromosomal deletions and amplifications that can cause an increased risk of genetic disease.

"Spectral Genomics' innovative technologies are highly complementary to our current molecular medicine and genetic screening offerings," said Robert F. Friel, president, PerkinElmer Life and Analytical Sciences.

"By enabling rapid surveys of the whole genome at high resolution, scientists can produce abundant, highly reproducible data in a fraction of the time required with standard methods, driving higher productivity in the lab."

Array-based karyotyping is widely expected to replace Florescent In-Situ Hybridization (FISH), G-banding microscopic analysis and other conventional forms of karyotyping in the cytogenetic market, which was valued at approximately $1.4 billion in 2004.

Advertisement